Leptina y factores de riesgo cardiovascular en pacientes con Lupus Eritematoso sistémico

Los individuos que presentan lupus eritematosos sistemico (LES) presentan una alta incidencia de padecer una enfermedad arterial coronaria y los factores de riesgo cardiovascular tradicionales no explican por completo esta alta morbi-mortalidad cardiovascular. La presente investigacion tiene como objetivo determinar los niveles sericos de leptina y su relacion con factores de riesgo cardiovascular en pacientes con LES. La muestra estuvo constituida por 15 mujeres con LES y 15 aparentemente sanas (grupo control, CTR). Se determino presion arterial, indice de masa corporal (IMC), indice cintura cadera (ICC), triglicerido (TG), colesterol total (CT), HDL-c, LDL-c, acido urico y leptina. 26,67% (4/15) de las pacientes con LES eran hipertensas diagnosticadas y con tratamiento anti-hipertensivo. IMC entre ambos grupos de estudio (25,33 ± 5,78 Kg/m2 vs 23,26 ± 2,37 Kg/ m2, P=0,43) no presento diferencia estadisticamente significativa, al igual que el ICC (0,79 ± 0,07 vs 0,73 ± 0,04, P=0,91). CT (140 ± 38 mg/dL vs 128 ± 49 mg/dL), TG (104 ± 71 mg/dL vs 72 ± 44 mg/dL), HDL-c (40 ± 9 mg/dL vs 41± 16 mg/dL), LDL-c (79 ± 34 mg/dL vs 72 ± 42 mg/dL) y VLDL-c (21 ± 14 mg/dL vs 14 ± 9 mg/dL) se encontraron dentro de los valores de referencia (P>0,05). Acido urico (3,58 ± 1,45 mg/dL vs 5,31 ± 8,58 mg/dL), 6,67% (1/15) del CTR presento hiperuricemia. Leptina en las pacientes con LES (22,25 ± 11,78 ng/dL) y CTR (15,59 ± 7,63 ng/dL). No se encontro una correlacion estadisticamente significativa entre las concentraciones serica de leptina con los factores de riesgo cardiovascular (P>0,05). Estos resultados sugieren que estas diferentes variables clinicas y bioquimicas determinadas en este estudio podrian actuar de manera independiente en el desarrollo de ateroesclerosis en sujetos que presente LES y en individuos aparentemente sanos.(AU) Individuals with systemic lupus erythematosus (SLE) have a high incidence of developing coronary artery disease and traditional cardiovascular risk factors do not explain this completed high cardiovascular morbidity and mortality. This research aims to determine the serum levels of leptin and its relation to cardiovascular risk factors in patients with SLE. The sample consisted of 15 women with SLE and 15 apparently healthy (control, CTR). Blood pressure, body mass index (BMI), waist-hip ratio (WHR), triglyceride (TG), total cholesterol (TC), HDL-c, LDL-c, uric acid and leptin was determined. 26.67% (4/15) of patients with SLE were diagnosed with hypertension and antihypertensive treatment. BMI between both study groups (25.33 ± 5.78 Kg/m2 vs 23.26 ± 2.37 Kg/m2, P = 0.43) showed no statistically significant, as the ICC difference (0.79 ± 0.07 vs 0.73 ± 0.04, P = 0.91). CT (140 ± 38 mg/dL vs 128 ± 49 mg/dL), TG (104 ± 71 mg/dL vs 72 ± 44 mg/dL), HDL-c (40 ± 9 mg/dL vs 41 ± 16 mg/dL), LDL-c (79 ± 34 mg/dL vs 72 ± 42 mg/dL) and VLDL-c (21 ± 14 mg/dL vs 14 ± 9 mg/dL) were within the reference values (P> 0.05). Uric acid (3.58 ± 1.45 vs 5.31 ± 8.58), 6.67% (1/15) of CTR filed hyperuricemia. Leptin in SLE patients (22.25 ± 11.78 ng/dL) and CTR (15.59 ± 7.63 ng/dL). No statistically significant correlation between serum leptin levels with cardiovascular risk factors (P >0.05) was found. These results suggest that these different clinical and biochemical variables determined in this study could act independently in the development of atherosclerosis in subjects who present LES and in apparently healthy individuals.(AU)